FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2241503054> ?p ?o ?g. }

• W2241503054 endingPage "LBA513" @default.
• W2241503054 startingPage "LBA513" @default.
• W2241503054 abstract "LBA513 Background: Neoadjuvant aromatase inhibitor (AI) therapy is a rational and effective approach to improving the breast conservation surgery (BCS) rate for postmenopausal patients with large, estrogen receptor (ER) rich breast cancers. Barriers to adopting this strategy include lack of experience in this management approach in the US and uncertainty regarding the comparative effectiveness of the three approved aromatase inhibitors for this indication. Methods: ACOSOG Z1031 is a multicenter, open-label, neoadjuvant phase III screening study that randomized postmenopausal women with clinical stage II/III ER rich (Allred score 6-8) breast cancer to 16 weeks of either exemestane (EXE) 25 mg daily, letrozole (LET) 2.5 mg daily, or anastrozole (ANA) 1 mg daily. At baseline study participants were either marginal for BCS (MBCS), candidates for mastectomy only (MO), or inoperable (IO). Planned enrolment was 125 patients per arm in order that the likelihood of the treatment with the “best” 16-week clinical response rate (based on caliper measurements) by WHO criteria (cRR) was included among the subset of treatments with “similar” cRR (90% power). Secondary endpoints included: extent of surgery, radiologic and pathologic response rates. Results: From 4/1/2006 to 10/1/2009, 377 postmenopausal women with clinical stage II or III ER rich breast cancer were enrolled. 374 women began treatment and were included in an intent-to-treat analysis. Median age was 66 yrs (range: 43-90 yrs), Median tumor size was 4.0 cm (range: 2-13 cm). The 16-week cRR was 60.5% (95%CI: 51.3-69.1%) for EXE; 70.9% (95% CI: 62.2-78.6%) for LET, and 66.7% (95% CI: 57.6-74.9%) for ANA. Seventeen patients did not have surgery due to refusal (12 pts), progression (3 pts) or other medical conditions (2 pts). The BCS rate was 78% (163/207) in MBCS group; 42% (77/163) in MO group; and 75% in IO group (3/4). Surgeons made the decisions regarding procedure choice 75% of the time in both the MBCS and the MO categories. Conclusions: This large multicenter screening trial selected non-steroidal AIs for further development due to their higher observed cRR. The study demonstrates that high response and breast conservation rates and low rates of disease progression can be achieved through patient selection based on high ER expression. We are currently refining our approach for early detection of poor response to AIs through an assessment of the tumor Ki67 proliferation index at 2 to 4 weeks (Z1031 Cohort B). [Table: see text]" @default.
• W2241503054 created "2016-06-24" @default.
• W2241503054 creator A5003916992 @default.
• W2241503054 creator A5006635460 @default.
• W2241503054 creator A5012394235 @default.
• W2241503054 creator A5017670549 @default.
• W2241503054 creator A5057135409 @default.
• W2241503054 creator A5063333233 @default.
• W2241503054 creator A5066125634 @default.
• W2241503054 creator A5072416022 @default.
• W2241503054 creator A5076263658 @default.
• W2241503054 creator A5080172326 @default.
• W2241503054 date "2010-06-20" @default.
• W2241503054 modified "2023-10-18" @default.
• W2241503054 title "ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer." @default.
• W2241503054 doi "https://doi.org/10.1200/jco.2010.28.18_suppl.lba513" @default.
• W2241503054 hasPublicationYear "2010" @default.
• W2241503054 type Work @default.
• W2241503054 sameAs 2241503054 @default.
• W2241503054 citedByCount "13" @default.
• W2241503054 countsByYear W22415030542012 @default.
• W2241503054 countsByYear W22415030542013 @default.
• W2241503054 countsByYear W22415030542014 @default.
• W2241503054 countsByYear W22415030542020 @default.
• W2241503054 countsByYear W22415030542022 @default.
• W2241503054 countsByYear W22415030542023 @default.
• W2241503054 crossrefType "journal-article" @default.
• W2241503054 hasAuthorship W2241503054A5003916992 @default.
• W2241503054 hasAuthorship W2241503054A5006635460 @default.
• W2241503054 hasAuthorship W2241503054A5012394235 @default.
• W2241503054 hasAuthorship W2241503054A5017670549 @default.
• W2241503054 hasAuthorship W2241503054A5057135409 @default.
• W2241503054 hasAuthorship W2241503054A5063333233 @default.
• W2241503054 hasAuthorship W2241503054A5066125634 @default.
• W2241503054 hasAuthorship W2241503054A5072416022 @default.
• W2241503054 hasAuthorship W2241503054A5076263658 @default.
• W2241503054 hasAuthorship W2241503054A5080172326 @default.
• W2241503054 hasConcept C121608353 @default.
• W2241503054 hasConcept C126322002 @default.
• W2241503054 hasConcept C143998085 @default.
• W2241503054 hasConcept C146357865 @default.
• W2241503054 hasConcept C151730666 @default.
• W2241503054 hasConcept C2775860665 @default.
• W2241503054 hasConcept C2776215463 @default.
• W2241503054 hasConcept C2777176818 @default.
• W2241503054 hasConcept C2777757722 @default.
• W2241503054 hasConcept C2778504769 @default.
• W2241503054 hasConcept C2778812593 @default.
• W2241503054 hasConcept C29456083 @default.
• W2241503054 hasConcept C530470458 @default.
• W2241503054 hasConcept C71924100 @default.
• W2241503054 hasConcept C86803240 @default.
• W2241503054 hasConceptScore W2241503054C121608353 @default.
• W2241503054 hasConceptScore W2241503054C126322002 @default.
• W2241503054 hasConceptScore W2241503054C143998085 @default.
• W2241503054 hasConceptScore W2241503054C146357865 @default.
• W2241503054 hasConceptScore W2241503054C151730666 @default.
• W2241503054 hasConceptScore W2241503054C2775860665 @default.
• W2241503054 hasConceptScore W2241503054C2776215463 @default.
• W2241503054 hasConceptScore W2241503054C2777176818 @default.
• W2241503054 hasConceptScore W2241503054C2777757722 @default.
• W2241503054 hasConceptScore W2241503054C2778504769 @default.
• W2241503054 hasConceptScore W2241503054C2778812593 @default.
• W2241503054 hasConceptScore W2241503054C29456083 @default.
• W2241503054 hasConceptScore W2241503054C530470458 @default.
• W2241503054 hasConceptScore W2241503054C71924100 @default.
• W2241503054 hasConceptScore W2241503054C86803240 @default.
• W2241503054 hasIssue "18_suppl" @default.
• W2241503054 hasLocation W22415030541 @default.
• W2241503054 hasOpenAccess W2241503054 @default.
• W2241503054 hasPrimaryLocation W22415030541 @default.
• W2241503054 hasRelatedWork W1491737910 @default.
• W2241503054 hasRelatedWork W1966100371 @default.
• W2241503054 hasRelatedWork W1992980782 @default.
• W2241503054 hasRelatedWork W2003583183 @default.
• W2241503054 hasRelatedWork W2015807835 @default.
• W2241503054 hasRelatedWork W2039236423 @default.
• W2241503054 hasRelatedWork W2090744251 @default.
• W2241503054 hasRelatedWork W2106580915 @default.
• W2241503054 hasRelatedWork W2123746076 @default.
• W2241503054 hasRelatedWork W2167166423 @default.
• W2241503054 hasVolume "28" @default.
• W2241503054 isParatext "false" @default.
• W2241503054 isRetracted "false" @default.
• W2241503054 magId "2241503054" @default.
• W2241503054 workType "article" @default.